Main Menu
— Ciechanover Institute of Precision and Regenerative Medicine —

The Ciechanover Institute of Precision and Regenerative Medicine of The Chinese University of Hong Kong, Shenzhen ("The Institute") headed by Professor Aaron Ciechanover was established on March 22nd, 2018. The Institute led by Professor Ciechanover, Nobel Prize Laureate in Chemistry in 2004, is the third Nobel laureate led institute of the University.


Professor Aaron Ciechanover, Nobel Laureate in Chemistry in 2004, serves as Distinguished Professor of Research at the Israel Institute of Technology. He is a Foreign Member of the American Academy of Sciences, and an Honorary Fellow of the American Academy of Arts and Sciences.


Ciechanover Institute of Precision and Regenerative Medicine has two major research focuses: precision medicine for the diagnosis and treatment of cancer and infectious disease; regenerative medicine for stem cell based treatment of stroke, Parkinson’s disease, Alzheimer’s disease, diabetes, etc. Precision medicine is an extremely important and hot frontier area that combines and transcends many research disciplines such as medicine, pharmaceutics, life science, genomics, big data and artificial intelligence. Regenerative medicine has become a vitally important area of medical research, development and commercialization. The Institute will seize the strategic opportunity vital to human health and high technology development and fully capitalize on the existing technological advantages and global influence of many world-renowned scientists of the Institute to become a world-class research and development organization within a short period of time. Through close collaboration with other research platforms of CUHK-Shenzhen such as Robot Institute of CUHK-Shenzhen, Shenzhen Research Institute of Big Data, Kobilka Institute of Innovative Drug Discovery, Arieh Warshel Institute of Computational Biology and with many companies in Shenzhen on technology transfer and commercialization, the Institute will play a leading role in the development of world-class biopharmaceutical and health industries in Shenzhen Municipality and the Greater Bay Area of Guangdong-Hong Kong-Macau.